Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Acamprosate
Drug ID BADD_D00016
Description Alcohol use disorder is responsible for a large worldwide burden of morbidity, premature mortality, and economic consequences resulting from accidents, violence, incarceration, decreased productivity, and increased healthcare spending.[A229073] Acamprosate, also known by the brand name Campral, is a drug used for the maintenance of alcohol abstinence. It is a structural analogue of the neurotransmitter γ-aminobutyric acid (GABA).[L31758] Acamprosate is the first medication specifically formulated for the maintenance of alcohol abstinence in ethanol-dependent patients after alcohol detoxification[A997], unlike [naltrexone] and [disulfiram]. It was first approved by the FDA in 2004 and initially marketed by Forest Laboratories.[L31783]
Indications and Usage For the maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at treatment initiation
Marketing Status Prescription; Discontinued
ATC Code N07BB03
DrugBank ID DB00659
KEGG ID D07058
MeSH ID D000077443
PubChem ID 71158
TTD Drug ID D0GC2M
NDC Product Code Not Available
Synonyms Acamprosate | Acamprostate | N-Acetylhomotaurine | N Acetylhomotaurine | Campral EC | N-Acetylhomotaurine, Magnesium (2:1) Salt | N-Acetylhomotaurine, Monolithium Salt | N Acetylhomotaurine, Monolithium Salt | N-Acetylhomotaurine, Zinc (2:1) Salt | Campral | N-Acetylhomotaurine, Monosodium Salt | N Acetylhomotaurine, Monosodium Salt | Sodium Acetylhomotaurine | Acetylhomotaurine, Sodium | Zulex | Acamprosate Calcium | Calcium Acetylhomotaurine | Acetylhomotaurine, Calcium | Calcium Acetylhomotaurinate | Acetylhomotaurinate, Calcium | N-Acetylhomotaurine, Calcium (2:1) Salt | Calcium Acetyl Homotaurinate | Acetyl Homotaurinate, Calcium | N-Acetylhomotaurine, Monopotassium Salt | N Acetylhomotaurine, Monopotassium Salt | Aotal | Regtect
Chemical Information
Molecular Formula C5H11NO4S
CAS Registry Number 77337-76-9
SMILES CC(=O)NCCCS(=O)(=O)O
Chemical Structure
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hyperuricaemia14.09.01.003--
Hypoaesthesia17.02.06.023--Not Available
Hyponatraemia14.05.04.002--
Hypotension24.06.03.002--
Hypothyroidism05.02.03.001; 14.11.01.012--
Hypovitaminosis14.12.01.001--Not Available
Immune system disorder10.02.01.001--Not Available
Increased appetite08.01.09.027; 14.03.01.003--Not Available
Infection11.01.08.002--Not Available
Influenza11.05.03.001; 22.07.02.001--Not Available
Injury12.01.08.004--Not Available
Insomnia17.15.03.002; 19.02.01.002--
Laryngospasm22.04.02.002--
Leukopenia01.02.02.001--Not Available
Libido decreased19.08.03.001; 21.03.02.005--
Libido increased19.08.03.002; 21.03.02.007--
Liver function test abnormal13.03.01.013--Not Available
Loss of consciousness17.02.04.004--Not Available
Lymphadenopathy01.09.01.002--Not Available
Lymphocytosis01.02.01.003--Not Available
Malaise08.01.01.003--
Mania19.16.02.002--
Melaena07.12.02.004; 24.07.02.013--Not Available
Menorrhagia21.01.03.002--
Mental disability26.01.01.001--Not Available
Metrorrhagia21.01.01.006--Not Available
Micturition urgency20.02.02.006--
Migraine17.14.02.001; 24.03.05.003--Not Available
Monocytosis01.02.01.004--Not Available
Mouth ulceration07.05.06.004--Not Available
The 4th Page    First    Pre   4 5 6 7    Next   Last    Total 7 Pages